Attacking Facioscapulohumeral muscular dystrophy (FSHD) at the source
Epigenetic gene regulation
RENOGENYX is a biotechnology company developing therapeutics for FSHD, which affects over 1 million people worldwide.
We are developing epigenetic tools to treat the root cause of disease.
Our most advanced preclinical program is a CRISPR-based approach to treat the underlying cause of FSHD.
Our vision is to bring new treatments and therapies to patients with FSHD.
There are over 50,000 people affected by FSHD in the USA and Canada, and another 1 million around the world.
Currently, there are no approved treatment options for FSHD, and we aim to change that.
By bringing together the best scientists, key opinion leaders and disease experts, and working directly with patient communities, clinicians, payors and other health stakeholders, we hope to make a transformational difference and change lives.
FSHD (facioscapulohumeral muscular dystrophy)
FSHD is an epigenetic gain-of-function neuromuscular disorder caused by the misexpression of DUX4 protein in skeletal muscle.
This website may contain general information relating to various medical conditions and their treatment. Such information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional. Patients should not use the information contained herein for diagnosing a health problem or disease. Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.